<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: We evaluated the feasibility of CEA/CK20 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and CEA/CA19-9 proteins as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers for <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> by detecting <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:chebi fb="2" ids="33699">mRNAs</z:chebi> in circulating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells and secreted <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific proteins in the peripheral blood of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Peripheral blood was obtained from 23 healthy volunteers and 46 colorectal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> patients on the day of initiation of adjuvant chemotherapy after surgery (stages I-III, n = 27) or on the first day of chemotherapy after diagnosis (stage IV, n = 19) </plain></SENT>
<SENT sid="2" pm="."><plain>Levels of CEA/CK20 <z:chebi fb="2" ids="33699">mRNA</z:chebi> in peripheral blood mononuclear cells (PBMCs) were determined with quantitative real-time reverse transcription polymerase chain reaction, and serum CEA/CA19-9 protein levels were determined by radioimmunoassay </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The detection sensitivity of CK20 <z:chebi fb="2" ids="33699">mRNA</z:chebi> was approximately 1 tumor cell in 1 × 10(7) PBMCs, and that of CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi> was approximately 1 tumor cell in 1 × 10(6) PBMCs </plain></SENT>
<SENT sid="4" pm="."><plain>Patients with <z:e sem="disease" ids="C0677950" disease_type="Neoplastic Process" abbrv="">stage IV colorectal cancer</z:e> had higher levels of CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi>, CK20 <z:chebi fb="2" ids="33699">mRNA</z:chebi>, and serum CEA than patients at stages I-III </plain></SENT>
<SENT sid="5" pm="."><plain>Peripheral blood CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels were predictive of overall survival, while serum protein levels of CEA and CA19-9 had no predictive value </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Peripheral blood CEA <z:chebi fb="2" ids="33699">mRNA</z:chebi> is a useful marker of overall survival in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> patients, that is sensitive and specific </plain></SENT>
</text></document>